Clinical trials: Adrenocortical Tumor
Adrenocortical Carcinoma
Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma
Adrenal cortical cancer is an extremely rare and highly aggressive malignancy with an incidence of 0.7-2 per million people · year and a 5-year overall survival rate of 15-44%, among which the 5-year survival rate of stage IV…
- Trial name
- NCT06587802
- Testing
- Triprolizumab, rodiotherapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sun Yat-sen University
Adrenocortical Carcinoma
Phase 1 Study of 68Ga-R8760
A Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers
- Trial name
- NCT05999292
- Testing
- 68Ga-R8760 injection at pre-defined dose levels, 68Ga-R8760 injection
- Where
- 2 sites in United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Radionetics Oncology
Adrenocortical Carcinoma
A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who received at least 1 but no more than 2 prior drug…
- Trial name
- GALACCTIC (NCT00924989)
- Testing
- OSI-906
- Where
- 35 sites in United States, Australia and 7 more
- Volunteers
- 139 people
- Sponsor
- Astellas Pharma Inc
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Adrenocortical Carcinoma
Cabozantinib in Advanced Adrenocortical Carcinoma
Adrenocortical carcinoma is an orphan malignant disease that has a dismal prognosis in advanced stages. Mitotane is the only approved treatment but is limited by severe toxicity.
- Trial name
- CaboACC (NCT03612232)
- Testing
- Cabozantinib-s-malate
- Where
- 2 sites in Germany
- Volunteers
- 37 people
- Sponsor
- Wuerzburg University Hospital
Adrenocortical Carcinoma
Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Despite complete resection of early-stage disease recurrence rates in ACC are very high (60%.70%).
- Trial name
- ACACIA (NCT03723941)
- Testing
- Cisplatin plus Etoposide, Observation or Mitotane
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Adrenocortical Carcinoma
Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)
This is a prospective randomized, double blind, placebo controlled phase II study planned in patients with advanced ACC. The study will be conducted at ASST Spedali Civili Hospital and University of Brescia in Brescia.
- Trial name
- PESETA (NCT05913427)
- Testing
- Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Adrenocortical Carcinoma
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare aggressive malignant tumor. According to the literature, the 5-year survival rate of ACC is 12%-47%.
- Trial name
- NCT04318730
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- West China Hospital
Adrenal Tumor, Primary Aldosteronism
Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
This research aims to establish clinical evidence for optimal treatment guidelines for adrenal diseases using real-world data. The approach involves building prospective and retrospective patient registries, which will be…
- Conditions
- Adrenal Tumor, Primary Aldosteronism, Cushing Syndrome, Pheochromocytoma
- Trial name
- NCT06229405
- Where
- South Korea
- Volunteers
- 8,200 people
- Sponsor
- Seoul National University Hospital
Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
This phase III clinical trial is studying how well cisplatin-based chemotherapy and/or surgery works in treating young patients with stage I, stage II, stage III or stage IV adrenocortical cancer.
- Conditions
- Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7
- Trial name
- NCT00304070
- Testing
- Cisplatin, Conventional Surgery, Doxorubicin Hydrochloride
- Where
- 91 sites in United States, Australia and 2 more
- Volunteers
- 78 people
- Sponsor
- Children's Oncology Group
Adrenocortical Carcinoma
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress Hormone (Cortisol).
- Trial name
- NCT04373265
- Testing
- Relacorilant, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Corcept Therapeutics
Adrenal Tumor, Adrenal Disease
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
The goal of this multicenter, observational, analytic, randomized clinical trial is to analyze the laparoscopic and robot-assisted method in the surgical treatment of patients with adrenal diseases.
- Conditions
- Adrenal Tumor, Adrenal Disease, Adrenal Mass, Adrenalectomy; Status
- Trial name
- NCT06050057
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University Hospital Olomouc
Adrenocortical Carcinoma
The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
This work will evaluate the adverse effects of mitotane treatment in patients treated for ACC with mitotane therapy. All of the individuals were treated at Ruijin Hospital between May 2023 and May 2024.
- Trial name
- MEET (NCT05839886)
- Volunteers
- 50 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Adrenocortical Carcinoma
European Multicenter Study on Role of Lymph Node Dissection in Surgical Management of Adrenal Cortical Carcinoma
This project will evaluate of the number of patients who underwent adrenalectomy for ACC in different European centers using the EUROCRINE® database. The analysis will focus on the extent of lymph nodal dissection (i.e.
- Trial name
- LACC (NCT05763524)
- Testing
- Adrenalectomy with or without lymphadenectomy
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Adrenocortical Carcinoma
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma
This work will evaluate the effects of mitotane treatment on serum protein concentrations in patients treated for ACC with mitotane therapy and compare them to patients with an adrenal neoplasm and pregnant cohort.
- Trial name
- MitoS-FP (NCT05344027)
- Testing
- Mitotane
- Where
- United Kingdom
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- King's College Hospital NHS Trust
Adrenocortical Carcinoma, Adrenocortical Cancer
Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)
Background: Adrenocortical cancer (ACC) is a rare tumor. The prognosis is very poor for people with advanced stages of ACC. Some people may live with ACC for years; others live for just months.
- Trial name
- NCT04447014
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma
Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma
The goal of this observational pilot study is to explore whether we can identify biomarkers predictive for the diagnosis of adrenocortical carcinoma in blood.
- Trial name
- AVS for ACC (NCT05660889)
- Testing
- Blood sampling.
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Erasmus Medical Center
Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Nodular Hyperplasia
First-in-human Evaluation of [18F]CETO
Purpose of this clinical phase 1 trial was to determine if para-chloro-2-[18F]fluoroethyletomidate positron emission computed tomography ([18F]CETO-positron emission computed tomography(PET)/computed tomography(CT)) can be used…
- Conditions
- Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Nodular Hyperplasia, Adrenal Cushing Syndrome, Non-Secretory Adrenal Adenoma
- Trial name
- NCT05361083
- Testing
- F18CETO
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E)
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E)
- Trial name
- NCT02637531
- Testing
- IPI-549 (eganelisib), Nivolumab
- Where
- 11 sites in United States
- Volunteers
- 219 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.